台湾透析人群丙型肝炎清除:协作照护模式
本研究在台湾彰化县31家透析机构3657例透析患者中实施多学科协作照护模式,提供丙肝筛查、诊断和直接抗病毒药物(DAA)治疗。全部患者完成筛查,DAA启动率和完成率分别为88.9%和94.0%,173例治疗患者中166例(96.0%)治愈,无病毒学失败。
要点
- 多学科协作可提高透析人群HCV筛查、诊断和治疗率。
- DAA治疗启动率88.9%,完成率94.0%,治愈率96.0%。
- 普遍可及DAA后慢性HCV累积治疗比升至89.1%。
核心结论
- 台湾协作照护模式将透析机构HCV诊断和治疗率提升至接近世界卫生组织目标水平。
研究设计与样本
- 质量改进研究,多学科协作团队包括肾科、消化科和公共卫生人员,覆盖彰化县全部透析患者。
主要发现
- 共纳入31家透析机构3657例患者,全部完成HCV筛查。
- DAA治疗启动率为88.9%,完成率为94.0%。
- 协作照护模式治愈173例中的166例(96.0%),无病毒学失败。
- 慢性HCV感染累积治疗比从2017年干扰素治疗前的5.3%升至2017-2018年限制DAA时的25.6%,2019年普遍可及DAA后升至89.1%。
关键数值与推荐
- DAA治疗启动率88.9%,完成率94.0%,治愈率96.0%。
- 慢性HCV累积治疗比:2017年前5.3%,2017-2018年25.6%,2019年89.1%。
临床怎么用
- 透析机构可借鉴协作照护模式,整合肾科、消化科和公共卫生资源,推进HCV筛查和DAA治疗。
局限性
- 协作照护项目对每年新入透析患者及早期慢性肾脏病患者的影響不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Hemodialysis facilities are high-risk environments for the spread of hepatitis C virus (HCV). Eliminating HCV from all dialysis facilities in a community may be achieved more effectively under a collaborative care model. STUDY DESIGN: Quality improvement study of multidisciplinary collaborative care teams including nephrologists, gastroenterologists, and public health practitioners. SETTING & PARTICIPANTS: All dialysis patients in Changhua County, Taiwan were treated using an interdisciplinary collaborative care model implemented within a broader Changhua-Integrated Program to Stop HCV Infection (CHIPS-C). QUALITY IMPROVEMENT ACTIVITIES: Provision of an HCV care cascade to fill 3 gaps, including screening and testing, diagnosis, and universal direct-acting antiviral (DAA) treatment implemented by collaborating teams of dialysis practitioners and gastroenterologists working under auspices of Changhua Public Health Bureau. OUTCOME: Outcome measures included quality indicators pertaining to 6 steps in HCV care ranging from HCV screening to treatment completion to cure. ANALYTICAL APPROACH: A descriptive analysis. RESULTS: A total of 3,657 patients from 31 dialysis facilities were enrolled. All patients completed HCV screening. The DAA treatment initiation rate and completion rate were 88.9% and 94.0%, respectively. The collaborative care model achieved a cure rate of 166 (96.0%) of 173 patients. No virologic failure occurred. The cumulative treatment ratios for patients with chronic HCV infection increased from 5.3% before interferon-based therapy (2017) to 25.6% after restricted provision of DAA (2017-2018), and then to 89.1% after universal access to DAA (2019). LIMITATIONS: Unclear impact of this collaborative care program on incident dialysis patients entering dialysis facilities each year and on patients with earlier stages of chronic kidney disease. CONCLUSIONS: A collaborative care model in Taiwan increased the rates of diagnosis and treatment for HCV in dialysis facilities to levels near those established by the World Health Organization.
引用
- Hu TH, Su WW, Yang CC, et al. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan. Am J Kidney Dis. 2021. PMID: 33940114. doi:10.1053/j.ajkd.2021.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。